Pharmather

PharmaTher Holdings Ltd. (OTCQB: PHRRF) has published its operational and audited financial results for fiscal year ended May 31, 2022.  The company, which focuses on delivering ketamine for treating mental health disorders  closed the annual period as follows:  Cash...

PharmaTher, a Toronto-based biotechnology company focused on discovering and developing drugs using Ketamine, received an Orphan Drug Designation (ODD) for a ketamine-based medicine to treat a rare seizure condition.  Status Epilepticus is characterized by a seizure lasting more than five...

This article was originally published on Microdose and appears here with permission. PharmaTher is one of the psychedelic medicine industry’s best kept secrets. With several Phase 2 trials in the works, a growing pipeline of both drug development and delivery methods, and a solid working...

PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced on Wednesday that the U.S. Food and Drug Administration (FDA) has accepted an application to proceed with a Phase 2...

Two of the most highly funded companies in the psychedelics space announced plans last week to list on the Nasdaq exchange. Months after submitting an application to uplist its shares from Toronto’s NEO exchange, MindMed (OTCQB: MMEDF) confirmed it will commence trading on the Nasdaq Capital...

The Psychedelics Sector Might Soon Get Its First ETF Financial services company Horizons ETFs Management filed documents with the Ontario Securities Commission for a psychedelics ETF, which is expected to go live on Jan. 15. The ‘Horizons Psychedelic Stock Index ETF’ would become the...

MDMA-assisted psychotherapy would result significantly more cost-effective than current available treatment options for post-traumatic stress disorder, according to a study distributed by the Multidisciplinary Association for Psychedelic Studies.  The peer-reviewed study, published Tuesday in...